The China liquid biopsy industry is becoming an important part of the country's expanding molecular diagnostics landscape. Market Research Future reports a market size of USD 636.93 million in 2024 and forecasts growth to USD 1.915 billion by 2035, representing a 10.53% CAGR during 2025–2035.

Innovation in genomic sequencing and biomarker analysis is supporting this expansion. Next-generation sequencing and digital PCR are improving the ability to identify genetic changes from liquid samples, while AI and advanced bioinformatics are helping make the resulting data easier to analyze.

Cancer diagnosis remains the main application, while treatment monitoring is becoming increasingly relevant for personalized cancer management. Blood samples continue to dominate, although urine and other sample types are being explored as less invasive alternatives for diagnostic testing.

Hospitals currently account for the largest share of end-use demand, supported by their diagnostic infrastructure and patient base. Diagnostic laboratories are also expanding as specialized molecular testing becomes more widely adopted. This creates opportunities for companies offering reliable and efficient liquid biopsy platforms.

Future growth could come from portable diagnostic devices, targeted biomarker testing, personalized medicine, and improved integration of liquid biopsy into clinical workflows. Continued advances in cancer genomics and non-invasive diagnostics are expected to create further opportunities for the Chinese market.

Dive into related studies for a broader industry perspective:

3D Printed Drug Market Forecast

Laboratory Filtration Market Outlook

Animal Biotechnology Market Analysis

Electronic Drug Delivery Systems Market Distribution

Medical Imaging Phantoms Market Size